Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, October 20, 2025

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke -recruiting

 

Your competent? doctor has been working on peptides for over a decade, right? Oh NO, INCOMPETENCE REIGNED AND NOTHING WAS DONE, CORRECT?

Let's see EXACTLY HOW LONG AND IN WHAT YOUR DOCTOR IS INCOMPETENT!
  • peptide (16 posts to January 2012)
  • nerinetide (10 posts to February 2020)

    • Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial

     November 2024

    Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

    ClinicalTrials.gov IDNCT05691244
    SponsorPharmazz, Inc.
    Information Provided byAnil Gulati, MD, PhD
    Study Start (Actual)2025-07-24
    Primary Completion (Estimated) 2026-09
    Study Completion (Estimated)2026-11
    Enrollment (Estimated)514
    Study TypeInterventional
    Last Update Posted2025-10-16

    Study Overview

    Brief Summary

    Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.

    To learn more, visitClinicalTrials.gov

    Posted by at
    Labels: , , , ,

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)